P2Y-like receptor, GPR105 (P2Y14), identifies and mediates chemotaxis of bone-marrowhematopoietic stem cells

  1. Byeong-Chel Lee1,4,
  2. Tao Cheng1,5,
  3. Gregor B. Adams1,
  4. Eyal C. Attar1,
  5. Nobuyuki Miura1,
  6. Sean Bong Lee2,
  7. Yoriko Saito1,
  8. Ivona Olszak1,
  9. David Dombkowski1,
  10. Douglas P. Olson1,
  11. Julie Hancock1,
  12. Peter S. Choi1,
  13. Daniel A. Haber2,
  14. Andrew D. Luster3, and
  15. David T. Scadden1,2,6
  1. 1Center for Regenerative Medicine and Technology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02129, USA 2 MGH Cancer Center, 3 Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02129, USA

Abstract

Hematopoiesis in mammals undergoes a developmental shift in location from fetal liver to bone marrow accompanied by a gradual transition from highly proliferative to deeply quiescent stem cell populations. P2Y receptors are G-protein-coupled nucleotide receptors participating in vascular and immune responses to injury. We identified a P2Y-like receptor for UDP-conjugated sugars, GPR105 (P2Y14), with restricted expression on primitive cells in the hematopoietic lineage. Anti-GPR105 antibody selectively isolated a subset of hematopoietic cells within the fetal bone marrow, but not in the fetal liver, that was enriched for G0 cell cycle status and for in vitro stem-cell-like multipotential long-term culture capability. Conditioned media from bone marrowstroma induced receptor activation and chemotaxis that was sensitive to Gαi and anti-receptor antibody inhibition. GPR105 is a G-protein-coupled receptor identifying a quiescent, primitive population of hematopoietic cells restricted to bone marrow. It mediates primitive cell responses to specific hematopoietic microenvironments and extends the known immune system functions of P2Y receptors to the stem cell level. These data suggest a newclass of receptors participating in the regulation of the stem cell compartment.

Keywords

Footnotes

  • Supplemental material is available at http://www.genesdev.org.

  • Article and publication are at http://www.genesdev.org/cgi/doi/10.1101/gad.1071503.

  • 4 Present address: Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA

  • 5 Present address: Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.

  • Corresponding author.

  • 6 E-MAIL scadden.david{at}mgh.harvard.edu; FAX (617) 726-4691.

    • Accepted May 13, 2003.
    • Received December 31, 2002.
| Table of Contents

G&D Most Read

View all ...

Life Science Alliance